Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study
Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study
复制标题
DOI：
10.1016/j.ajem.2011.06.003
复制
发表时间：
2012-09-01
影响因子：
3.6
通讯作者：
Koishi, Keiko
中科院分区：
文献类型：
--
作者：
Nishiyama, Tomoki;Kohno, Yumiko;Koishi, Keiko
目的：我们假设，抗凝血酶是更有效的弥散性血管内凝血（DIC）比加贝酯甲磺酸，这是一种蛋白酶抑制剂，建议从以前的研究。最初，我们比较了抗凝血酶和甲磺酸加贝酯治疗感染相关的DIC.Methods的效果：16例成人患者诊断为DIC感染谁被评估为急性DIC评分4或更高的入院重症监护病房分为抗凝血酶治疗和甲磺酸加贝酯治疗组。在入院当天和之后的第1、3、5和7天测量白色血细胞计数、C-反应蛋白、血小板计数、抗凝血酶、纤维蛋白和纤维蛋白原降解产物、D-二聚体、纤维蛋白原、凝血酶抗凝血酶复合物、纤溶酶原复合物、凝血酶原时间和活化部分凝血酶时间。死亡率超过28天也compared.Results：血小板计数和抗凝血酶显着较高的抗凝血酶组在第7天和第5和7天，分别。抗凝血酶组第1天抗凝血酶升高至正常水平，加贝酯组第7天抗凝血酶升高至正常水平。C-反应蛋白、纤维蛋白原降解产物、D-二聚体、凝血酶抗凝血酶复合物、纤溶酶原复合物和凝血酶原时间在抗凝血酶组较低，但差异无显著性。28天的死亡率为2 8在抗凝血酶组和加贝酯组8，但他们没有显着difficulty.Conclusions：抗凝血酶可能是一个更有效的治疗凝血和纤溶障碍比加贝酯在感染相关的DIC，但没有差异，在28天的死亡率。(C)2012 Elsevier Inc. All rights reserved.
Purpose: We hypothesized that antithrombin is more effective for disseminated intravascular coagulation (DIC) than is gabexate mesilate, which is a protease inhibitor, suggested from the previous studies. Initially, we compared the effects of antithrombin and gabexate mesilate for treating infection-related DIC.Methods: Sixteen adult patients with a diagnosis of DIC with infection who were assessed with an acute DIC score 4 or higher at the admission to the intensive care unit were divided into antithrombin-treated and gabexate mesilate-treated groups. White blood cell counts, C-reactive protein, platelet counts, antithrombin, fibrin and fibrinogen degradation product, D-dimer, fibrinogen, thrombin antithrombin complex, plasmin plasminogen complex, prothrombin time, and activated partial thrombin time were measured on the day of admission and on days 1, 3, 5, and 7 thereafter. Mortality over 28 days was also compared.Results: Platelet counts and antithrombin were significantly higher in the antithrombin group on day 7 and on days 5 and 7, respectively. Antithrombin increased to the normal level on day 1 in the antithrombin group but on day 7 in the gabexate mesilate group. C-reactive protein, fibrinogen degradation product, D-dimer, thrombin antithrombin complex, plasmin plasminogen complex, and prothrombin time were lower in the antithrombin group; but the differences were not significant. The 28-day mortality was 2 of 8 in the antithrombin group and 3 of 8 in the gabexate mesilate group, but they were not significantly different.Conclusions: Antithrombin may be a more effective treatment for coagulation and fibrinolysis disorders than gabexate mesilate in infection-related DIC, but there was no difference in 28-day mortality. (C) 2012 Elsevier Inc. All rights reserved.